Literature DB >> 8581288

Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.

G H Allcock1, T D Warner, J R Vane.   

Abstract

1. Endothelin-1 (ET-1) produces vasoconstriction, via activation of ETA and ETB receptors on vascular smooth muscle, and vasodilatation via ETB receptors on endothelial cells. Here we have used the ETA receptor-selective antagonist, BQ-123, the ETB receptor-selective antagonist, BQ-788 and the ETA/ETB receptor non-selective antagonist, PD 145065, to study the role of these receptors in mediating the haemodynamic changes induced by an infusion of ET-1 to the anesthetized ganglion-blocked rat. 2. Infusion of ET-1 (10 pmol kg-1 min-1) increased the mean arterial pressure (MAP) by 57.5 +/- 5.1 mmHg over 70 min. This pressor response was reduced by about 50% by coinfusion of BQ-123 (10 mmol kg-1 min-1), but was unaffected by either BQ-788 (10 nmol kg-1 min-1) or PD 145065 (10 nmol kg-1 min-1). 3. After infusion of ET-1 for 70 min the cardiac output had fallen from 102.6 +/- 11.3 to 55.7 +/- 7.6 ml min-1 and the total peripheral resistance had increased from 3.24 +/- 0.6 to 10.0 +/- 0.8 mmHg ml-1 min-1 (per 100g body weight). BQ-123 decreased the magnitudes of these changes whereas BQ-788 potentiated them. PD 145065 was without effect. 4. ET-1 increased the vascular resistances of all the organs studied except the brain and stomach. These changes were attenuated by BQ-123 in the kidneys, skin, adrenal glands and caecum and potentiated by BQ-788 in the kidneys, small intestine, large intestine and mesentery. PD 145065 had little effect on the individual tissues. 5. Thus, BQ-123, a selective ETA receptor antagonist, inhibits the pressor and vascular constrictor effects of ET-1 more actively than PD 145065. As BQ-788 potentiates some of the vasoconstrictor effects of ET-1 and increases the effects of ET-1 on total peripheral resistance, the predominant role of ETB receptors in the rat circulation is to limit the pressor effects of ET-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581288      PMCID: PMC1909069          DOI: 10.1111/j.1476-5381.1995.tb15099.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.

Authors:  G M Rubanyi; M A Polokoff
Journal:  Pharmacol Rev       Date:  1994-09       Impact factor: 25.468

2.  Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.

Authors:  T D Warner; G H Allcock; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

3.  The involvement of endothelial dysfunction, nitric oxide and prostanoids in the rat gastric microcirculatory responses to endothelin-1.

Authors:  J Lopez-Belmonte; B J Whittle
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

4.  Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

Authors:  K Ishikawa; M Ihara; K Noguchi; T Mase; N Mino; T Saeki; T Fukuroda; T Fukami; S Ozaki; T Nagase
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

5.  SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

Authors:  E H Ohlstein; P Nambi; S A Douglas; R M Edwards; M Gellai; A Lago; J D Leber; R D Cousins; A Gao; J S Frazee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

7.  Contribution of endogenous generation of endothelin-1 to basal vascular tone.

Authors:  W G Haynes; D J Webb
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

8.  Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin.

Authors:  E Lawrence; S D Brain
Journal:  Eur J Pharmacol       Date:  1994-07-21       Impact factor: 4.432

9.  Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett; A P Davenport; L Edvinsson
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.

Authors:  R P Wellings; R Corder; T D Warner; J P Cristol; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

View more
  9 in total

1.  Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the rat.

Authors:  H Ruetten; C Thiemermann
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Assessment of the effects of endothelin-1 and magnesium sulphate on regional blood flows in conscious rats, by the coloured microsphere reference technique.

Authors:  P A Kemp; S M Gardiner; J E March; P C Rubin; T Bennett
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction.

Authors:  G A Gray; E J Mickley; D J Webb; P E McEwan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Role of endothelin ET(A)- and ET(B)-receptors in haemodynamic compensation following haemorrhage in anaesthetized rats.

Authors:  Beatriz Palacios; Su Lin Lim; Catherine C Y Pang
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice.

Authors:  Xiaoyan Wang; Yingjin Luo; Crisanto S Escano; Zhiwei Yang; Laureano Asico; Hewang Li; John E Jones; Ines Armando; Quansheng Lu; David R Sibley; Gilbert M Eisner; Pedro A Jose
Journal:  Hypertension       Date:  2010-04-19       Impact factor: 10.190

6.  Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.

Authors:  V Niranjan; S Télémaque; D deWit; R D Gerard; M Yanagisawa
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

7.  Involvement of the metabolic sensor GPR81 in cardiovascular control.

Authors:  Kristina Wallenius; Pia Thalén; Jan-Arne Björkman; Petra Johannesson; John Wiseman; Gerhard Böttcher; Ola Fjellström; Nicholas D Oakes
Journal:  JCI Insight       Date:  2017-10-05

8.  ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin.

Authors:  Edward W Inscho; John D Imig; Anthony K Cook; David M Pollock
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

9.  Distortion of KB estimates of endothelin-1 ETA and ETB receptor antagonists in pulmonary arteries: Possible role of an endothelin-1 clearance mechanism.

Authors:  James A Angus; Richard J A Hughes; Christine E Wright
Journal:  Pharmacol Res Perspect       Date:  2017-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.